Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Nat Commun. 2023 Oct 24;14(1):6747. doi: 10.1038/s41467-023-42596-6.
Plasma amyloid-β (Aβ)42, phosphorylated tau (p-tau)181, and neurofilament light chain (NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these biomarkers can predict AD in Chinese populations is yet to be fully explored. We therefore tested the performance of these plasma biomarkers in 126 participants with preclinical AD and 123 controls with 8-10 years of follow-up from the China Cognition and Aging Study. Plasma Aβ42, p-tau181, and NfL were significantly correlated with cerebrospinal fluid counterparts and significantly altered in participants with preclinical AD. Combining plasma Aβ42, p-tau181, and NfL successfully discriminated preclinical AD from controls. These findings were validated in a replication cohort including 51 familial AD mutation carriers and 52 non-carriers from the Chinese Familial Alzheimer's Disease Network. Here we show that plasma Aβ42, p-tau181, and NfL may be useful for predicting AD 8 years before clinical onset in Chinese populations.
血浆淀粉样蛋白-β（Aβ42）、磷酸化tau（p-tau）181 和神经丝轻链（NfL）是阿尔茨海默病（AD）有前途的生物标志物。然而，这些生物标志物是否能预测中国人群中的 AD 尚未得到充分探索。因此，我们在中国认知老化研究中对 126 名有临床前 AD 的参与者和 123 名有 8-10 年随访的对照者进行了这些血浆生物标志物的性能测试。血浆 Aβ42、p-tau181 和 NfL 与脑脊液的对应物显著相关，且在有临床前 AD 的参与者中发生了显著改变。血浆 Aβ42、p-tau181 和 NfL 的联合成功地区分了临床前 AD 与对照组。这些发现在中国家族性阿尔茨海默病网络的一个包含 51 个家族性 AD 突变携带者和 52 个非携带者的复制队列中得到了验证。在这里，我们表明血浆 Aβ42、p-tau181 和 NfL 可能有助于预测中国人群临床发病前 8 年的 AD。
